Answers are grounded in this paper and cite their sources.
Radionuclide therapy is a clinically effective approach for precision cancer treatment. However, its efficacy is severely compromised by the hypoxic tumor microenvironment and intrinsic DNA self-repair mechanisms. Moreover, a single treatment modality is often insufficient to eradicate tumors. To address these challenges, we designed and constructed a multifunctional dendritic mesoporous silica (dendritic mesoporous silica nanoparticles)-based delivery system co-loaded with the chemotherapeutic agent 5-fluorouracil (5-FU) and catalase (CAT). The delivery system surface was modified with human serum albumin and hyaluronic acid (HA), followed by radiolabeling with the radionuclide 131I to enable tumor-targeted delivery, hypoxia alleviation, and synergistic radiotherapy−chemotherapy effects. This radionuclide delivery system exhibits excellent radiolabeling stability, biocompatibility, and SPECT imaging properties. It leverages CAT to efficiently catalyze the decomposition of endogenous H2O2 in the tumor microenvironment to generate O2, thereby significantly relieving tumor hypoxia. HA modification confers superior active tumor-targeting capability, while sustained release of 5-FU under acidic conditions at the tumor site effectively inhibits DNA replication. Both in vitro and in vivo experiments demonstrate that this system synergistically enhances the efficacy of 131I brachytherapy and 5-FU chemotherapy, leading to marked tumor growth inhibition with low systemic toxicity. Overall, this study overcomes the hypoxic tumor barrier and achieves synergistic targeted therapy combined with chemoradiotherapy, offering a novel strategy for effective and low-toxicity clinical treatment of solid tumors.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: